Back to search results

Enteral Nutrition for Allogeneic Stem Cell Transplant Patients

This study is looking at whether providing special nutrition through a feeding tube (called Enteral Nutrition) can help patients undergoing an allogeneic hematopoietic stem cell transplant (a type of bone marrow transplant). You might be able to join if you are an adult with a blood cancer or serious blood disorder and are planning to have this type of transplant. The study compares Enteral Nutrition to the usual care, where nutrition is given if you can't eat enough. Researchers want to see if Enteral Nutrition can reduce severe gut graft-versus-host disease (GVHD), a common complication, within 100 days after your transplant. The current recruitment status is unclear.

Study design
This is a randomized controlled phase II study planning to enroll 112 adult patients.
What's involved
Participants will receive either standard care or Enteral Nutrition via a feeding tube starting the day after transplant for at least 7 days, usually until engraftment.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured at 100 days post-transplant.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07315165

Enteral Nutrition Versus Standard of Care in Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting
PHASE2Ages 19+InterventionalSupportive care
University of Nebraska
~112 participants
Updated 2026-08-31 on ClinicalTrials.gov
What's tested:Enteral Nutrition

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Stage 3-4 Acute GVHD of Lower Gut
Measured over 100 Days post- transplant

Conditions

Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)

Explore related trials

Hematologic NeoplasmHematopoietic and Lymphoid Cell Disorder

NCT07315165

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Fred & Pamela Buffet Cancer Center

    Omaha, Nebraskastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Michael Haddadin, MD · PRINCIPAL_INVESTIGATOR · University of Nebraska

Who to contact

Krishna vamsi Gottipati, MS
[email protected]
(402) 5593518
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of a hematological condition or serious blood disorder
Patient planned for an allogeneic hematopoietic stem cell transplant
Any conditioning regimen or graft source

Exclusion

Uncorrected anatomical deformity of the nose, nasopharynx, esophagus, or stomach that could prevent proper placement of a nasogastric tube.
Chronic gastrointestinal conditions causing malabsorption or need for nutritional supplementation, e.g., celiac disease, short gut syndrome, chronic use of total parental nutrition or enteral nutrition for 3 or more months. Uncorrected anatomical deformity may include any known significant deviated nasal septum, large nasal polyps or other masses, or nasal or oropharyngeal trauma.

What this trial measures

  • Incidence of Stage 3-4 Acute GVHD of Lower Gut100 Days post- transplant

    Cumulative incidence will be calculated as the time to stage 3-4 acute GVHD of the lower gut for each of the study arms.